The Asia Pacific Joint Pain Injections Market would witness market growth of 8.6% CAGR during the forecast period (2022-2028).
Injections are useful because they can momentarily lessen swelling and pain in inflamed joints. Therapeutic joint injections are minimally invasive, target the afflicted area directly, and provide localized relief with few to no adverse effects. Joint injections are frequently advised for patients seeking long-term relief from pain that does not improve with more traditional therapies, such as oral anti-inflammatory drugs. Most people have pain reduction after a peripheral intra-articular injection for two to six months.
Injections can reduce pain and inflammation to a sufficient degree to allow other treatments for the underlying problem to be used, even though they do not treat the condition that causes joint pain. Physical treatment helps strengthen muscles and improve mobility in the afflicted joint, enhancing the positive benefits of joint injections. Physical therapy sessions could be advised in addition to a period of joint rest. In order to enhance the biomechanics of a joint, patients may also be encouraged to undertake lifestyle adjustments, such as decreasing weight or switching up their footwear. The goal is to limit or eliminate the need for additional injections by including joint injections in a more comprehensive therapeutic strategy.
China has one of the world's fastest-aging populations. By 2040, 28% of the population of China is projected to be over 60 due to increased life expectancy and declining birth rates. This significant population change presents new opportunities and difficulties for socioeconomic growth and public health. Therefore, developing an integrated system that addresses the social and medical requirements of the elderly while guaranteeing universal access to healthcare, regardless of location, is particularly crucial. The prevalence of illnesses calling for joint pain injections may increase as the population becomes older. As a result, the Asia Pacific region's market for joint pain injections might expand.
The China market dominated the Asia Pacific Joint Pain Injections Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $717.6 Million by 2028. The Japan market is registering a CAGR of 7.9% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 9.2% during (2022 - 2028).
Based on Injection Type, the market is segmented into Interleukin Inhibitors, Hyaluronic Acid Injections, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Joint Type Channel, the market is segmented into Knee & Ankle, Shoulder & Elbow, Hip Joint, Facet Joints of the Spine, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Joint Pain Injections Market is Projected to reach USD 9.9 Billion by 2028, at a CAGR of 7.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioventus Inc., Pacira BioSciences, Inc., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc., Anika Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Eli Lilly And Company, Ferring Holdings SA, and Sanofi S.A.
By Injection Type
By Distribution Channel
By Joint Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 